Arog Pharmaceuticalsincis A Clinical Stage Biopharmaceutical Company Based In Dallastexasfounded In 2010The Company Focuses On Developing Novel Therapeutics To Address Unmet Medical Needsparticularly In Oncologyarog Is Advancing Its Lead Candidatecrenolaniban Oral Tyrosine Kinase Inhibitor Targeting Flt3 Mutations In Acute Myeloid Leukemiaaml Crenolanib Is Under Investigation For Measurable Residual Disease In Aml And Has Shown Promise In Treating Various Solid Tumorsincluding Gastric Cancer And Lung Cancerthe Drug Received Fda Fast Track Designation For Specific Gastrointestinal Stromal Tumors In 2016Arog Emphasizes Targeted Drug Development Through Collaborations With Researchers And Institutions To Facilitate The Clinical Application Of Its Therapieswith A Small Team Of Approximately Nine Employeesarog Operates In A Competitive Landscape Alongside Larger Pharmaceutical Companies
United States
